CD274 and neoplasm: The principle of anti-PD-L1 antibody immunotherapy is to block the combination of PD-L1 and PD-1, changing the inherent connection of immune cells and tumor cells, which eventually changes the tumor microenvironment, and stimulates the huge potential of immune cells to attack the tumor [39].